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T
yrosine kinases (TKs) are found 
only in metazoans, where 
they regulate multiple critical 
multicellular functions, including 
growth, differentiation, apoptosis, 
adhesion, and mobility [1]. As these 
functions also play critical roles in 
tumorigenesis, TKs are the prototypical 
class of oncogenes involved in many 
human malignancies. Of the 90 TKs, 
58 are receptor TKs grouped into 
20 subfamilies, while the others are 
non-receptor TKs grouped into ten 
subfamilies.
EGFRs and Cancer
The epidermal growth factor receptor 
(EGFR) family is subclass I of the 
receptor TK superfamily, and consists 
of four members, EGFR (ErbB1), HER2 
(ErbB2), EGFR3 (ErbB3), and EGFR4 
(ErbB4). Ligand binding results in 
homo- or heterodimerization and 
activation of the highly conserved 
intracellular kinase domain, resulting 
in phosphorylation of speciﬁ  c tyrosine 
residues that serve as docking sites of 
proteins whose recruitment activates 
a multitude of downstream signaling 
pathways [2]. Adenosine triphosphate 
(ATP), the phosphate donor, lodges 
in a cleft between the two roughly 
globular lobes of the TK domain. 
Deranged family member signaling 
in tumors often involves EGFR and 
HER2. Increased activity of EGFR 
signaling, often associated with adverse 
prognosis, has been detected in many 
tumors, a ﬁ  nding that resulted in the 
selection of this molecule as one of 
the ﬁ  rst targets for designed therapies 
[3]. Deranged signaling may result 
from activating mutations, increased 
gene copy number, or autocrine 
loops. Targeted therapies that have 
undergone extensive clinical trials fall 
into two major categories: humanized 
forms of monoclonal antibodies that 
prevent ligand–receptor interaction, 
and small molecule inhibitors (tyrosine 
kinase inhibitors [TKIs]) such as 
erlotinib or geﬁ  tinib, which reversibly 
bind to the ATP binding cleft (Figure 
1A), preventing phosphorylation and 
subsequent downstream signaling. 
While antibody administration has 
been disappointing as a therapy for 
lung cancer, treatment with TKIs is 
associated with responses, occasionally 
dramatic, in highly select patient 
subpopulations. Less than 18 months 
ago, it was found that activating 
mutations in the TK domain of the 
gene occurred in a subset of non-small-
cell lung cancer (NSCLC), especially 
adenocarcinomas, and predicted, 
though not precisely, the response 
to small molecule inhibitors [4–6]. 
In this issue of PLoS Medicine, Heidi 
Greulich and colleagues [7] suggest 
that all EGFR mutations are not created 
equal, and that different mutation 
classes respond differently to speciﬁ  c 
inhibitors.
Kinase-Activating Mutations 
in Lung Cancer
TK domains are highly conserved and 
consist of two approximately globular 
structures, a smaller N lobe and a 
larger C lobe (Figure 1A). Activating 
mutations in the TK domain of EGFR 
are limited to the ﬁ  rst four exons, and 
show a remarkable structural diversity, 
including point mutations, deletions, 
and insertions. Mutations are largely, 
if not entirely, conﬁ  ned to NSCLC 
(reports of occasional mutations in 
other tumor types await conﬁ  rmation). 
Two types, deletions in exon 19 and 
a single point mutation in exon 21, 
L858R (Figure 1A), account for about 
85% of all mutations [8]. A modest 
number of insertions/duplications are 
found in exon 20. Occasional point 
mutations may occur at multiple other 
sites and account for the remainder. 
Activating mutations confer ligand 
independence, and selectively mobilize 
Akt and STAT signaling pathways, 
which promote cell survival, but have 
little effect on MAP kinase regulated 
signaling, which induces proliferation. 
These mutations induce a dependency 
on or “addiction” to EGFR survival 
signals, especially when combined 
with allele-speciﬁ  c ampliﬁ  cation, and 
inhibition of those signals by TKIs may 
contribute to the drugs’ efﬁ  cacy [9]. 
Some evidence existed prior to the 
report by Greulich et al. [7] that the 
different classes of speciﬁ  c mutations 
may vary in their clinicopathological 
correlations, downstream signaling 
events, or responsiveness to TKIs. 
The two major classes of mutations, 
deletions in exon 19 or the L858R 
point mutation in exon 21, may result 
in differential autophosphorylation of 
speciﬁ  c phosphate residues, resulting 
in differences in downstream signaling 
[10]. A point mutation has been 
described in exon 20, T790M, that is 
associated with resistance to TKIs (most 
tumors that respond to TKIs eventually 
recur) [11,12]. Some preliminary 
evidence suggest that patients whose 
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NSCLC tumors harbor the L858R 
mutation have a better prognosis than 
those with exon 19 deletions [8].
Characterizing Speciﬁ  c Mutations
Using two in vitro model systems, an 
immortalized bronchial epithelial line 
and a mouse ﬁ  broblast line, Greulich 
and collaborators demonstrated the 
transforming abilities of mutant forms 
of EGFR (the G719S point mutation 
in exon 18, the L858R point mutation 
in exon 21, a representative deletion 
mutant in exon 19, and a representative 
insertion mutant in exon 20), but not 
of the wild-type EGFR after transfer by 
retroviral vector [7]. Transformation 
was accompanied by phopshorylation 
and activation of the appropriate 
downstream signaling pathways. Thus, 
representative mutations in all four 
affected exons of EGFR demonstrated 
in vitro transforming activity. However, 
while the wild-type form of the receptor 
requires ligand activation, cells with the 
mutant form demonstrated constitutive 
activation. These ﬁ  ndings may 
explain why the monoclonal antibody 
cetuximab has little effect on lung 
cancer cells with activating mutations, 
but seems to inhibit other tumors 
(such as colorectal carcinomas) that 
overexpress wild-type EGFR.
While all of the mutant forms tested 
demonstrated transforming activity, 
they showed marked differences in 
their responses to TKIs. As previously 
demonstrated [4,5,12], cells with 
the deletion mutant and the point 
mutation L858R were inhibited by 
the TKIs geﬁ  tinib and erlotinib, while 
the exon 20 insertion mutation was 
resistant. Three patients with lung 
adenocarcinoma and with exon 20 
deletion mutants of EGFR failed to 
show a clinical response (contrary to 
the expectation that, since the general 
response rate of tumors with EGFR 
mutations to TKIs is about 80%, two 
or all three of these particular ones 
would be responsive). However, the 
cells with the insertion mutation 
demonstrated increased sensitivity to 
the irreversible inhibitor CL-387,785, 
previously demonstrated to be active 
against cells with both an activating 
mutation and the resistance-associated 
point mutation T790M on exon 20 
[11]. Thus, two very different forms of 
mutations in exon 20, a point mutation 
and an insertion, demonstrated relative 
resistance to the clinically widely used 
reversible TKIs, but exhibited sensitivity 
to the experimental drug Cl-387,785.
Implications for Treatment of Lung 
Cancer Patients
What lessons can we learn from the 
report by Greulich and colleagues? 
First, we have conﬁ  rmation that all 
of the recognized classes of EGFR 
TK domain mutations described 
in lung cancers are activating; and 
second, cells (and perhaps tumors) 
with mutations involving exon 20 
demonstrate a very different pattern of 
response to TKIs than those harboring 
other mutations. There are important 
clinical implications from these and 
related ﬁ  ndings. While CL-387,785 
is not currently approved for clinical 
use, it or related compounds may be 
useful for overcoming resistance in 
the future. However, not all cases of 
resistant tumors have an identiﬁ  ed 
molecular basis. Multiple other factors 
may modulate the response to TKIs, 
including deregulation of downstream 
pathways, ampliﬁ  cation of target or 
related genes, heterodimerization 
with other gene family members, and 
autocrine loops. On a related note, 
mutations of HER2 have been described 
in a small percentage of NSCLC 
tumors [13]. Of interest, all described 
mutations to date are insertion/
duplications in exon 20 in a region 
homologous to the site of insertions 
in the EGFR gene (Figure 1B). We 
predict that NSCLC cells harboring 
HER2 mutations will prove resistant to 
the reversible TKIs, but will be sensitive 
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Figure 1. Schematic of the EGFR Gene with Locations of the Mutation Types 
(A) Mutations are limited to the ﬁ  rst four exons (exons 18–21) of the tyrosine kinase (TK) domain 
encompassing all of the N lobe and part of the C lobe. The three major types of mutations, 
accounting for about 94% of all mutations, and their approximate frequencies are indicated by the 
larger arrows. The locations of most of the described rarer point mutations are indicated by smaller 
arrows. The mutations target regions critical for phosphorylation events (the A-loop, P-loop, and the 
αC helix). Data from Shigematsu and colleagues [8]. 
(B) Schematic of exon 20 of the EGFR and HER2 genes, indicating the location of the described 
in-frame insertions/duplications (arrowheads), the T790M mutation (large arrow) and rarer point 
mutations (small arrows). PLoS Medicine  |  www.plosmedicine.org 1087 November 2005  |  Volume 2  |  Issue 11  |  e377
to CL-387,785 (or a similar irreversible 
inhibitor with HER2 speciﬁ  city). 
The multiple mechanisms, actual 
or hypothetical, that can result in 
resistance to targeted therapies [14] 
make it unlikely that a single agent 
will sufﬁ  ce for tumor control in all 
cases. As stated in a recent review, 
“TKs are now regarded as excellent 
targets for cancer chemotherapy, but 
reality lies somewhere between the 
extremes of triumph and tribulation” 
[14]. Overcoming resistance by 
presently identiﬁ  ed and by as yet 
unknown mechanisms presents many 
challenges to physicians, scientists, 
and pharmaceutical and biomedical 
industries.  
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